ACS Applied Materials & Interfaces · 2020 · 73 citations · 29 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyDrug DeliveryCancer Drug DeliveryCancer MetabolismCancer NanomedicineMetabolic ReprogrammingNanoparticle DesignTargeted Cancer TherapyAnticancer ActivityAnticancer ChemotherapyAnticancer Drug LoadingLiposomesTargeted LiposomesTumor Microenvironment-responsive TargetingTumor-targeted Drug Delivery
Tumor cells usually display metabolic, genetic, and microenvironment-related alterations, which are beneficial to tumor proliferation, tumor development, and resistance occurrence. Many transporters and enzymes, including ATB0,+, xCT, and matrix metalloproteinases (MMPs), are involved in the altered cell metabolism and tumor microenvironment and often abnormally upregulated in malignant tumors. Meanwhile, these dysregulated transporters and enzymes provide targets not only for a pharmacological blockage to suppress tumor progress but also for tumor-specific delivery. Although transporters and MMPs have been widely reported for antitumor drug delivery, the feasibility of utilizing two strategies has never been elucidated yet. Herein, we developed an MMP2-activated and ATB0,+-targeted liposome with doxorubicin and sorafenib (DS@MA-LS) loaded for optimal tumor drug delivery for cancer therapy. DS@MA-LS was designed to prolong blood circulation and deshield the PEG shell from MMP2 cleavage to expose lysine and target overexpressed ATB0,+ for enhanced tumor distribution and cancer cellular uptake. Besides the anticancer effects of loaded drugs, the endocytosed liposomes could further increase ROS production and suppress the antioxidant system to amplify oxidative stress. As expected, DS@MA-LS displayed enhanced targeted drug delivery to tumor sites with the MMP2-controlled ligand exposure and ATB0,+-mediated uptake. More importantly, DS@MA-LS successfully inhibited the tumor growth and cancer cell proliferation both in vitro and in vivo by enhancing apoptosis and ferroptosis, which thanks to the increased ROS generation and impaired GSH synthesis synergistically amplified oxidative stress. Our results suggested that the tumor microenvironment-responsive, multistaged nanoplatform, DS@MA-LS, has excellent potential for optimal drug delivery and enhanced cancer treatment.
29
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Scott J. Dixon, Kathryn M. Lemberg, Michael R. Lamprecht et al. · Cell · 2012 · 18.1K citations · Full text
Crystal structure of the human glucose transporter GLUT1
Dong Deng, Chao Xu, Pengcheng Sun et al. · Nature · 2014 · 770 citations
Engineering Magnetosomes for Ferroptosis/Immunomodulation Synergism in Cancer
Fan Zhang, Feng Li, Guihong Lu et al. · ACS Nano · 2019 · 360 citations
Medicine, Immunology, Oncology +17